FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12200
Abstract: Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI), is an effective treatment for non‐small‐cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance.… read more here.
Keywords: tumor development; gefitinib; lung tumor; therapy ... See more keywords
Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1121
Abstract: Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and gefitinib, the two first‐generation EGFR‐TKIs, exhibit significant clinical responses for… read more here.
Keywords: egfr tkis; gefitinib; lung cancer; cancer ... See more keywords
Gefitinib-Induced Cutaneous Toxicities in Brown Norway Rats Are Associated with Macrophage Infiltration.
Sign Up to like & getrecommendations! Published in 2020 at "Inflammation"
DOI: 10.1007/s10753-020-01281-2
Abstract: Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Skin toxicity is the major adverse… read more here.
Keywords: gefitinib induced; gefitinib; macrophage infiltration; cutaneous toxicities ... See more keywords
STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Human cell"
DOI: 10.1007/s13577-021-00582-4
Abstract: Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to… read more here.
Keywords: hcc827 cells; inhibitor; gefitinib; stat3 inhibitor ... See more keywords
Human serum albumin nanoparticulate system with encapsulation of gefitinib for enhanced anti-tumor effects in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Drug Delivery Science and Technology"
DOI: 10.1016/j.jddst.2019.06.011
Abstract: Abstract Gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has showed remarkable activity in non-small cell lung cancer patients with tumors carrying sensitive EGFR mutation. However, Iressa® tablets present problems, including insolubility,… read more here.
Keywords: small cell; albumin; lung cancer; gefitinib ... See more keywords
A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of proteomics"
DOI: 10.1016/j.jprot.2019.01.009
Abstract: KDAC inhibitors (KDACi) overcome gefitinib primary resistance in non-small cell lung cancer (NSCLC) including mutant-KRAS lung adenocarcinoma. To identify which proteins are involved in the restoration of this sensitivity and to provide new therapeutic targets… read more here.
Keywords: kras mutated; gefitinib; kdac; primary resistance ... See more keywords
The Unique Spatial‐Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.11.020
Abstract: Introduction: Adjuvant gefitinib therapy prolonged disease‐free survival in patients with resected early‐stage EGFR‐mutation positive NSCLC in the ADJUVANT study (CTONG 1104). However, treatment failure patterns after gefitinib therapy are less well characterized. Methods: Overall, 222… read more here.
Keywords: gefitinib; treatment; failure patterns; post ... See more keywords
Gefitinib reduces oocyte quality by disturbing meiotic progression.
Sign Up to like & getrecommendations! Published in 2021 at "Toxicology"
DOI: 10.1016/j.tox.2021.152705
Abstract: Gefitinib is a first-line anti-cancer drug for the treatment of advanced non-small cell lung cancer (NSCLC). It has been reported that gefitinib can generate several drug-related adverse effects, including nausea, peripheral edema, decreased appetite and… read more here.
Keywords: gefitinib; meiotic progression; oocyte quality; gefitinib reduces ... See more keywords
PPAR&ggr; agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR‐TKI‐resistant lung adenocarcinoma cells via the PPAR&ggr;/PTEN/Akt pathway
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2017.10.024
Abstract: ABSTRACT Development of acquired resistance to EGFR‐TKI therapy continues to be a serious clinical problem in Lung adenocarcinoma management. Peroxisome proliferator‐activated receptor gamma (PPAR&ggr;) agonists demonstrate anti‐tumor activity likely via transactivating genes that regulate cell… read more here.
Keywords: ppar; lung adenocarcinoma; gefitinib; ppar ggr ... See more keywords
Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Non-Small Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.0c08069
Abstract: Despite the effective targeting of epidermal growth factor receptor (EGFR), the use of gefitinib (GFT) for non-small cell lung cancer (NSCLC) treatment meets a failure due to the insufficient drug accumulation in the tumor region.… read more here.
Keywords: non small; gefitinib; natural borneol; lung cancer ... See more keywords
PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.
Sign Up to like & getrecommendations! Published in 2021 at "Acta pharmacologica Sinica"
DOI: 10.1038/s41401-021-00638-z
Abstract: Recent studies show that intracellular accumulation of cholesterol leads to acquired resistance to gefitinib in non-small cell lung cancer (NSCLC) cells. In this study we investigated how to regulate the cholesterol levels in gefitinib-resistant NSCLC… read more here.
Keywords: ppar; apoptosis; gefitinib; cholesterol ... See more keywords